Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
X
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
https://pharmaphorum.com/esmo-2016/cancer-market-commentary-roches-tecentriq-muscles-nsclc/
